Table 2 Inclusion and exclusion criteria

Inclusion Criteria

 ● CAD patients with hypertensive LVH who receive PCI.

 ● Male and female aged 18–70 years.

 ● Coronary stenosis is greater than 70% before PCI performed, and < 20% after PCI, with no need for other angioplasty.

 ● Trimetazidine naive.

 ● Provided informed consent.

Exclusion Criteria

 ● Utilization of trimetazidine, coenzyme Q10 or other medications which would affect cardiac metabolism.

 ● Concomitant with other causes for left ventricular hypertrophy, such as aortic constriction, hypertrophic cardiomyopathy and cardiac valvular disease.

 ● Concomitant with other causes for myocardial ischemia, such as congenital heart disease, rheumatic heart disease, dilated cardiomyopathy.

 ● Presentation with an acute myocardial infarction.

 ● Severe liver and kidney dysfunction (hepatic transaminase levels > 3 x ULN, bilirubin > 1.5 x ULN, eGFR < 30 mL/min/1.73m²).

 ● Heart function defined as New York Heart Association IV, or LVEF < 30%.

 ● Pregnancy or lactating, or possibility of a future pregnancy.

 ● History of cancer.

 ● Life expectancy less than 12 months.